Evidence map›Paper›PMID 22796860›Full record

ArticleChest2012

Preventing VTE in Outpatients With Cancer.

Alok A Khorana, Alex C Spyropoulos, Jeffrey Zwicker, Gary H Lyman, Charles W Francis

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Alok A KhoranaJames P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY. Electronic address: alok_khorana@urmc.rochester.edu.
Alex C SpyropoulosJames P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY.
Jeffrey ZwickerDivision of Hemostasis-Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Gary H LymanDuke University and Duke Cancer Institute, Durham, NC.
Charles W FrancisJames P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY.

Funding

Venous Thrombosis in Cancer Outpatients: Prevention and Role of Tissue FactorR01HL095109 · NHLBI · UNIVERSITY OF ROCHESTER · PI FRANCIS, CHARLES W. · 2008 to 2012
$3.2M
Programs in Clinical Effectiveness of Cancer PharmacogenomicsUC2CA148041 · NCI · DUKE UNIVERSITY · PI GINSBURG, GEOFFREY S · 2010 to 2010
$2.0M
Programs in Clinical Effectiveness of Cancer PharmacogenomicsRC2CA148041 · NCI · DUKE UNIVERSITY · PI GINSBURG, GEOFFREY S · 2009 to 2009
$2.0M
Risk Factors for Venous Thromboembolism in Cancer Patients Receiving ChemotherapyK23CA120587 · NCI · UNIVERSITY OF ROCHESTER · PI KHORANA, ALOK A · 2006 to 2010
$649k
NCI NIH HHS K23 CA120587NCI NIH HHS RC2 CA148041NCI NIH HHS UC2 CA148041NHLBI NIH HHS R01 HL095109
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Evidence-Based MedicineSocieties, MedicalFibrinolytic AgentsHumansVenous ThromboembolismFibrinolytic Agents

Identifiers

PMID22796860
PMCPMC3418862

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.